Yourgene Health Share Discussion Threads

[scotty1] 03/6/2019 08:32

Correct cottoner 👍

[cottoner] 03/6/2019 08:30

News might not be imminent , but he knows what's happening.

[downyr] 03/6/2019 08:11

But surely that must mean no news imminent or he would not be able to buy

[scotty1] 03/6/2019 07:25

AR buying another 900k @ 11p,follow the money 😉

[scotty1] 31/5/2019 14:20

Good sensible post from over the road.

notaflipper

Posts: 882
Opinion: No Opinion
Price: 10.75
Getting bit silly againToday 14:04

Given that the market makers seem to have pegged the bid to 10.96 whilst we await the brokers report I haven’t been monitoring this BB but it seems that some people have worked themselves up into a state and are distorting the facts to the detriment of their investment . We
are all awaiting a revised brokers report and this is a frustrating experience for all however some of the emotion seems a bit overdone given that this report should be imminent. Unfortunately when this report is now released some may have switched off due to this negative sentiment

With respect to the product range YourGene is not a one trick pony . Elucigene has launched 36 commercial products. Its main product categories cover Cystic Fibrosis Kits, Rapid Aneuploidy Analysis, Reproductive Health, Genetic Disease
Diagnosis. Elucigene's product offering plus IONA and Sage test means that the product portfolio is close to 40. Although not announced via an RNS the Taipei laboratory is now offering expanded services such as BRCA1 and BRCA2 screening, Oncomine testing verified
by TMO, Cancer Hotspot screening, Reproductive Health, Preimplantation genetic screening (PGS), Cardiomyopathy and Sudden Death Syndrome. So the service/product offering has been significantly expanded this year.

Sales forecasts should be expected to be over £15m up from Finncapp's £13.5M in FY2020 compared to £8.9m in FY2019. The 8.9m revenues was up 45% from FY2019.The Enlarged company would have sales of £12.5 million in FY2019. Elucigene have
no public sales forecasts so even if we assume they're flat at £3.6m the Enlarged Company will have improved sales forecasts of £16.1M in FY2020E and £20.8M in FY2021E. Break-even to be achieved this year. With sales of £16m in FY2020E the current share price on a
fully diluted basis is £70m. This gives a 4.5 EV/sales multiple of 4.4. At 17p an EV of £99m would be 6. Even at 17p this would be very low

[twix386] 31/5/2019 13:53

Pretty dismal share price and no material NIPT contract win rns'd for a YEAR!

[scotty1] 29/5/2019 09:51

Kidney Function Test Market To Reach USD 1061.0 Million By 2026

May 28, 2019 12:45 ET | Source: Reports And Data

Further key findings from the report suggest

As per the Centre for Disease Control and Prevention 44% of the diabetic patients suffered from End-Stage Renal Disease in U.S. in 2017 as diabetes damage the blood vessels of kidneys leading to an improper functioning of kidneys contributing to the risk for kidney disorders
North America has the highest market share of 34.9% in the Kidney Function Test Market because of the existence of higher number of population facing kidney malfunctions and also due to the establishment of various major market players in this region
The major players of the market have been using inorganic methods for the purpose of growth and increase in the foothold in the market. One such instance has been the acquisition of Elucigene Diagnostics by Yourgene diagnostics, both being players in the molecular diagnostic methods in April 2019
The disposables that are used as a product for the purpose of Kidney Function Test have been growing as consumables and producing sector as well. The market share of these disposables is forecasted to be 35% and is seen to be growing in a positive trend
According to the European Renal Association and the European Dialysis and Transplant Association (ERA-EDTA) in the year 2017, approximately 70 million people in Europe suffered from some or the other type of kidney disease which has led to an emerging market even in Europe
Out of the many tests that are available for the purpose of kidney function testing, clearance tests account to hold 37.4% of the market share accounting to be the highest of all the other existing tests.
There have been developments not only for machinery and devices but also for various other diagnostic measures. One such development was the introduction of a home kit using smartphones for urinalysis. In August 2018, Siemens Healthcare announced an integration with Healthy.io’s system for smartphone in order to make urinalysis easy for patients

[scotty1] 24/5/2019 16:08

Manchester startups: Tech businesses you need to know in 2019
May 23, 2019

Yourgene Health (formerly Premaitha)
Yourgene develops genetic services for healthcare professionals. Its first offering, the Iona test, is a non-invasive prenatal screen for genetic abnormalities including Down’s syndrome. Where standard testing is 85% accurate, Iona is 99% accurate—therefore fewer women are sent for amniocentesis and CVS, which are invasive screens that carry a small risk of miscarriage.

Yourgene hopes to apply its technology to other fields, including oncology: a new project in Taiwan has already begun work with newly-diagnosed breast cancer and leukaemia patients.

[scotty1] 24/5/2019 12:01

Delayed 900k buy from after hrs y'day shown 😉

[scotty1] 24/5/2019 07:54

I see there was a good late after hrs buy y'day,seems there could be a background buyer being filled then 🤔 as i said could see the share price move up before the issue of the new note by Stifel Nicolaus or even new deal news,we will see.

[scotty1] 24/5/2019 07:54

duplicate post

[hjb1] 23/5/2019 15:06

oh ye of little faith Twix..lol Anyway prob be back down later!

[twix386] 23/5/2019 14:59

Wow! Ticked up!!C'mon Ngen.:-)

[twix386] 23/5/2019 13:45

Yup, the curse of Ngen posting seems unbroken.

[scotty1] 23/5/2019 11:43

Hmm bit surprised we haven't ticked down given the sells unless of course we have a buyer in the background being filled 🤔

[twix386] 22/5/2019 14:37

Quiet so ;-)

[scotty1] 22/5/2019 10:29

All quite in here,so what have we, BGF Investment Management invests 4m in the placing who indecently usually put their money in private stocks so pretty unusual for it to invest in a quoted company so all looks pretty good there.Then we have the new broker Stifel Nicolaus were we should be getting a note out within the next week or 2,got a feeling in my water we may have a bit of a run up as we approach the issue of that note 😉

[ngen yap] 15/5/2019 22:34

I sense our little YGEN (not so little anymore) have stabilised post recent corporate transaction, and anticipate a steady upward trend from his base. I am looking out for large deals in US and Brazil, more research test assignments and continued growth through existing, now enlarged, distribution channels. Interestingly, one can buy the shares at cheaper price than Elucigene owners who got them at 11.7p. Recent directors' buys very encouraging, most telling, Stephen little's addition. We will have our day!

[mhw28865] 13/5/2019 14:37

It does twix but share price went up at the same time. V strange

[twix386] 13/5/2019 14:17

That looks like s big 2m sell?

[mhw28865] 09/5/2019 07:07

Directors buy they obviously think its time to buy as well!

[hjb1] 07/5/2019 19:56

yep! then time to buy ..

[dave444] 07/5/2019 19:26

Getting closer

[hjb1] 07/5/2019 14:44

perhaps the muppet who votes me down on every post would like to give his reasons? lol

[hjb1] 07/5/2019 14:33

what are the downsides here now anyone? not a lot, surely!